N
NRx Pharmaceuticals, Inc. (NRXP)
NCM – Real Time Price. Currency in USD
2.87
+0.05 (1.77%)
At close: May 12, 2026, 4:00 PM EDT
2.99
+0.12 (4.18%)
Pre-market: May 13, 2026, 6:11 AM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
2.87
+0.05 (1.77%)
At close: May 12, 2026, 4:00 PM EDT
2.99
+0.12 (4.18%)
Pre-market: May 13, 2026, 6:11 AM EDT
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine. It also provides precision-based interventional psychiatry services to patients with treatment-resistant depression and PTSD using a combination of neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy; ketamine infusion therapy; stellate ganglion blocks; Spravato administration; psychotherapy; and medication management. The company has a development and license agreement with Glytech LLC. NRx Pharmaceuticals, Inc. was founded in 2015 and is headquartered in Wilmington, Delaware.
| Name | Position |
|---|---|
| Dr. Dennis K. McBride Ph.D. | Chief Strategy Officer & Director |
| Dr. Jonathan C. Javitt M.D., M.P.H. | Co-Founder, Chairman, CEO & Chief Scientist Officer |
| Dr. Philip T. Lavin Ph.D. | Chief Methodologist |
| Dr. Riccardo Panicucci Ph.D. | Chief Manufacturing & Technology Officer |
| Mr. Glenn Tyson | Chief Commercial Officer |
| Mr. Joseph M. Casper | Chief Operating Officer |
| Mr. Michael S. Abrams M.B.A. | CFO & Treasurer |
| Prof. Joshua C. Brown M.D., Ph.D. | Chief Medical Innovation Officer |
| Suzanne Messere | Investor Relations |
| Date | Type | Document |
|---|---|---|
| 2026-03-24 | 8-K | nrxp20260324_8k.htm |
| 2026-03-23 | 10-K | nrxp20251231_10k.htm |
| 2026-02-24 | DEFA14A | nrxp20260224_defa14a.htm |
| 2026-02-23 | DEF 14A | nrxp20260218_def14a.htm |
| 2026-02-17 | 8-K | nrxp20260216c_8k.htm |
| 2026-02-13 | PRE 14A | nrxp20260209_pre14a.htm |
| 2026-02-02 | 8-K | nrxp20260202_8k.htm |
| 2026-01-16 | 8-K | nrxp20260115_8k.htm |
| 2025-12-29 | 8-K | nrxp20251229_8k.htm |
| 2025-12-12 | S-3/A | nrxp20251211_s3a.htm |